Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibrx Biosciences, Inc.INBX · Entity 4576 | Director · Chief Executive Officer | October 14, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibrx Biosciences, Inc.
Report date October 14, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Lappe Family Trust | 745,588 |
Last balance in matching sequence
After 2026-10-14 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-10-14 · Purchase · Acquired 2,470 · Balance 743,018 F1: The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Row 2 · 2026-10-14 · Purchase · Acquired 2,470 · Balance 745,488 F3: The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Row 3 · 2026-10-14 · Purchase · Acquired 100 · Balance 745,588 F2: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Lappe Descendants' Trust | 170,000 |
Last balance in matching sequence
After 2026-10-14 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 4 · 2026-10-14 · Purchase · Acquired 2,449 · Balance 167,449 F1: The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F4: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Row 5 · 2026-10-14 · Purchase · Acquired 2,451 · Balance 169,900 F3: The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F4: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Row 6 · 2026-10-14 · Purchase · Acquired 100 · Balance 170,000 F4: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. |
| Common StockSEC Table I · non-derivative | IndirectThe Mark Paul Lappe Roth IRA | 54,865 |
Reported balance
Holding disclosure · report date 2026-10-14 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 54,865 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F2: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.
F3: The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F4: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inhibrx, Inc.
Report date May 30, 2024 · Filed May 30, 2024
Section 16 reporting ended · disclosed 2024-05-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Lappe Family Trust | 0 |
Reported balance
After 2024-05-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-05-30 · Disposition to issuer · Disposed 2,486,192 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F3: These securities were directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 0 |
Reported balance
After 2024-05-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-05-30 · Disposition to issuer · Disposed 500,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F4: These securities were directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. |
| Common StockSEC Table I · non-derivative | IndirectThe Mark Paul Lappe Roth IRA | 0 |
Reported balance
After 2024-05-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-05-30 · Disposition to issuer · Disposed 59,462 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.30 · Expires 2033-01-03 | Direct | 0 |
Reported balance
After 2024-05-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-30 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer's common stock under such stock option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F5: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.63 · Expires 2031-01-15 | Direct | 0 |
Reported balance
After 2024-05-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-30 · Disposition to issuer · Disposed 145,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8: This stock option was canceled in the Merger and converted into the right to receive the contingent payment described in the following sentence. If the Milestone is achieved, the cash amount to be paid in respect of each such stock option will be equal to (x) $35.00 (representing the sum of the Closing Amount of $30.00 and the Milestone Payment of $5.00) minus (y) the option exercise price per share, subject to applicable tax withholding. F7: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments thirty-six (36) months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company.
F3: These securities were directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.
F4: These securities were directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.
F5: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
F6: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer's common stock under such stock option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option.
F7: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments thirty-six (36) months thereafter.
F8: This stock option was canceled in the Merger and converted into the right to receive the contingent payment described in the following sentence. If the Milestone is achieved, the cash amount to be paid in respect of each such stock option will be equal to (x) $35.00 (representing the sum of the Closing Amount of $30.00 and the Milestone Payment of $5.00) minus (y) the option exercise price per share, subject to applicable tax withholding.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2026 Filed Oct 14, 2026 22:58 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 100 | $85.76 | $8,576.00 |
DisclosureSEC source: 0001366074-26-000006 · wk-form4_1792018692.xml · nonDerivative · entry 6 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Lappe Descendants' Trust Disclosed balance after: 170,000 F4 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Read SEC document |
| October 14, 2026 Filed Oct 14, 2026 22:58 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 2,451 | $85.00 | $208,333.04 |
DisclosureSEC source: 0001366074-26-000006 · wk-form4_1792018692.xml · nonDerivative · entry 5 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Lappe Descendants' Trust Disclosed balance after: 169,900 F3 · price: The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F4 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Read SEC document |
| October 14, 2026 Filed Oct 14, 2026 22:58 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 2,449 | $84.07 | $205,889.14 |
DisclosureSEC source: 0001366074-26-000006 · wk-form4_1792018692.xml · nonDerivative · entry 4 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Lappe Descendants' Trust Disclosed balance after: 167,449 F1 · price: The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F4 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Read SEC document |
| October 14, 2026 Filed Oct 14, 2026 22:58 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 100 | $85.76 | $8,576.00 |
DisclosureSEC source: 0001366074-26-000006 · wk-form4_1792018692.xml · nonDerivative · entry 3 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 745,588 F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| October 14, 2026 Filed Oct 14, 2026 22:58 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 2,470 | $85.00 | $209,948.02 |
DisclosureSEC source: 0001366074-26-000006 · wk-form4_1792018692.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 745,488 F3 · price: The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| October 14, 2026 Filed Oct 14, 2026 22:58 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 2,470 | $84.07 | $207,654.63 |
DisclosureSEC source: 0001366074-26-000006 · wk-form4_1792018692.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 743,018 F1 · price: The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 28, 2026 Filed Sep 28, 2026 21:47 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 3,000 | $101.70 | $305,106.00 |
DisclosureSEC source: 0001366074-26-000004 · wk-form4_1790632047.xml · nonDerivative · entry 4 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 740,548 F5 · price: The shares were purchased in multiple transactions at prices ranging from $101.44 to $101.80 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 28, 2026 Filed Sep 28, 2026 21:47 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 1,500 | $98.88 | $148,320.45 |
DisclosureSEC source: 0001366074-26-000004 · wk-form4_1790632047.xml · nonDerivative · entry 3 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 737,548 F4 · price: The shares were purchased in multiple transactions at prices ranging from $98.69 to $99.21 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 25, 2026 Filed Sep 28, 2026 21:47 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 2,176 | $99.60 | $216,726.99 |
DisclosureSEC source: 0001366074-26-000004 · wk-form4_1790632047.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 736,048 F3 · price: The shares were purchased in multiple transactions at prices ranging from $99.335 to $100.00 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 25, 2026 Filed Sep 28, 2026 21:47 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 3,324 | $98.87 | $328,630.25 |
DisclosureSEC source: 0001366074-26-000004 · wk-form4_1790632047.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 733,872 F1 · price: The shares were purchased in multiple transactions at prices ranging from $98.27 to $99.26 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 20:04 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 9,681 | $112.28 | $1,087,001.07 |
DisclosureSEC source: 0001366074-26-000002 · wk-form4_1788897881.xml · nonDerivative · entry 6 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 730,548 F7 · price: The shares were purchased in multiple transactions at prices ranging from $112.15 to $112.44 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 20:04 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 1,219 | $111.88 | $136,382.33 |
DisclosureSEC source: 0001366074-26-000002 · wk-form4_1788897881.xml · nonDerivative · entry 5 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 720,867 F6 · price: The shares were purchased in multiple transactions at prices ranging from $111.15 to $112.07 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 20:04 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 500 | $108.24 | $54,117.50 |
DisclosureSEC source: 0001366074-26-000002 · wk-form4_1788897881.xml · nonDerivative · entry 4 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 719,648 F5 · price: The shares were purchased in multiple transactions at prices ranging from $108.05 to $108.66 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 20:04 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 1,100 | $107.12 | $117,836.29 |
DisclosureSEC source: 0001366074-26-000002 · wk-form4_1788897881.xml · nonDerivative · entry 3 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 719,148 F4 · price: The shares were purchased in multiple transactions at prices ranging from $106.6225 to $107.57 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 20:04 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 6,605 | $100.64 | $664,719.27 |
DisclosureSEC source: 0001366074-26-000002 · wk-form4_1788897881.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 718,048 F3 · price: The shares were purchased in multiple transactions at prices ranging from $100.095 to $100.99 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 20:04 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 5,895 | $99.29 | $585,342.85 |
DisclosureSEC source: 0001366074-26-000002 · wk-form4_1788897881.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 711,443 F1 · price: The shares were purchased in multiple transactions at prices ranging from $98.88 to $99.8316 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 16, 2024 Filed Sep 16, 2024 17:12 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 13,037 | $17.13 | $223,323.81 |
DisclosureSEC source: 0002007919-24-000049 · wk-form4_1726521147.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 705,548 F3 · price: The shares were purchased in multiple transactions at prices ranging from $16.70 to $17.695, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 17:12 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 26,963 | $15.05 | $405,793.15 |
DisclosureSEC source: 0002007919-24-000049 · wk-form4_1726521147.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 692,511 F1 · price: The shares were purchased in multiple transactions at prices ranging from $15.00 to $15.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 10, 2024 Filed Sep 10, 2024 17:00 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 8,500 | $15.19 | $129,115.00 |
DisclosureSEC source: 0002007919-24-000045 · wk-form4_1726002051.xml · nonDerivative · entry 3 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 665,548 F4 · price: The shares were purchased in multiple transactions at prices ranging from $15.01 to $15.26, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 17:00 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 9,500 | $15.21 | $144,495.00 |
DisclosureSEC source: 0002007919-24-000045 · wk-form4_1726002051.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 657,048 F3 · price: The shares were purchased in multiple transactions at prices ranging from $15.08 to $15.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 17:00 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 26,000 | $15.29 | $397,540.00 |
DisclosureSEC source: 0002007919-24-000045 · wk-form4_1726002051.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 647,548 F1 · price: The shares were purchased in multiple transactions at prices ranging from $15.04 to $15.70, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 17:31 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 4,712 | $16.31 | $76,852.72 |
DisclosureSEC source: 0001739614-24-000037 · wk-form4_1725399057.xml · nonDerivative · entry 4 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Lappe Descendants' Trust Disclosed balance after: 165,000 F5 · price: The shares were purchased in multiple transactions at prices ranging from $16.115 to $16.465, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 17:31 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 15,288 | $15.66 | $239,410.08 |
DisclosureSEC source: 0001739614-24-000037 · wk-form4_1725399057.xml · nonDerivative · entry 3 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Lappe Descendants' Trust Disclosed balance after: 160,288 F4 · price: The shares were purchased in multiple transactions at prices ranging from $15.115 to $16.11, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Read SEC document |
| August 30, 2024 Filed Sep 3, 2024 17:31 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 10,000 | $14.02 | $140,200.00 |
DisclosureSEC source: 0001739614-24-000037 · wk-form4_1725399057.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Lappe Descendants' Trust Disclosed balance after: 145,000 F3 · price: The shares were purchased in multiple transactions at prices ranging from $13.96 to $14.13, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 17:31 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 10,000 | $14.03 | $140,300.00 |
DisclosureSEC source: 0001739614-24-000037 · wk-form4_1725399057.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Lappe Descendants' Trust Disclosed balance after: 135,000 F1 · price: The shares were purchased in multiple transactions at prices ranging from $13.9079 to $14.245, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 16:29 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 12,945 | $12.93 | $167,378.85 |
DisclosureSEC source: 0002007919-24-000038 · wk-form4_1724358581.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · The Mark Paul Lappe Roth IRA Disclosed balance after: 54,865 F2 · price: The shares were purchased in multiple transactions at prices ranging from $12.82 to $13.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 16:29 UTC | Inhibrx Biosciences, Inc. INBX · Entity 4576 | PurchaseCommon Stock | 27,055 | $12.97 | $350,903.35 |
DisclosureSEC source: 0002007919-24-000038 · wk-form4_1724358581.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · The Mark Paul Lappe Roth IRA Disclosed balance after: 41,920 F1 · price: The shares were purchased in multiple transactions at prices ranging from $12.77 to $13.14, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 30, 2024 Filed May 30, 2024 18:22 UTC | Inhibrx, Inc. INBX · Entity 90351 | Disposition to issuerStock Option (right to buy) · Derivative | 145,000 | Not disclosed Strike: $33.63 | Not disclosed |
DisclosureSEC source: 0000950142-24-001500 · es240484812_4-lappe.xml · derivative · entry 5 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,000 shares Expires 2031-01-15 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8 · price: This stock option was canceled in the Merger and converted into the right to receive the contingent payment described in the following sentence. If the Milestone is achieved, the cash amount to be paid in respect of each such stock option will be equal to (x) $35.00 (representing the sum of the Closing Amount of $30.00 and the Milestone Payment of $5.00) minus (y) the option exercise price per share, subject to applicable tax withholding. F7 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments thirty-six (36) months thereafter. Read SEC document |
| May 30, 2024 Filed May 30, 2024 18:22 UTC | Inhibrx, Inc. INBX · Entity 90351 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $23.30 | Not disclosed |
DisclosureSEC source: 0000950142-24-001500 · es240484812_4-lappe.xml · derivative · entry 4 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2033-01-03 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer's common stock under such stock option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F5 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document |
| May 30, 2024 Filed May 30, 2024 18:22 UTC | Inhibrx, Inc. INBX · Entity 90351 | Disposition to issuerCommon Stock | 59,462 | $30.00 | $1,783,860.00 |
DisclosureSEC source: 0000950142-24-001500 · es240484812_4-lappe.xml · nonDerivative · entry 3 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · The Mark Paul Lappe Roth IRA Disclosed balance after: 0 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · price: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. Read SEC document |
| May 30, 2024 Filed May 30, 2024 18:22 UTC | Inhibrx, Inc. INBX · Entity 90351 | Disposition to issuerCommon Stock | 500,000 | $30.00 | $15,000,000.00 |
DisclosureSEC source: 0000950142-24-001500 · es240484812_4-lappe.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 0 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · price: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F4 · ownership.nature: These securities were directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Read SEC document |
| May 30, 2024 Filed May 30, 2024 18:22 UTC | Inhibrx, Inc. INBX · Entity 90351 | Disposition to issuerCommon Stock | 2,486,192 | $30.00 | $74,585,760.00 |
DisclosureSEC source: 0000950142-24-001500 · es240484812_4-lappe.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 0 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · price: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F3 · ownership.nature: These securities were directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| May 30, 2024 Filed May 30, 2024 18:10 UTC | Inhibrx Biosciences, Inc. INXB · Entity 4576 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $15.86 | $0.00 |
DisclosureSEC source: 0000950142-24-001493 · es240484863_4-lappe.xml · derivative · entry 4 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-05-30 F4 · date: This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi. F5 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document |
| May 29, 2024 Filed May 30, 2024 18:10 UTC | Inhibrx Biosciences, Inc. INXB · Entity 4576 | GrantCommon Stock | 14,865 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001493 · es240484863_4-lappe.xml · nonDerivative · entry 3 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · The Mark Paul Lappe Roth IRA Disclosed balance after: 14,865 F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. Read SEC document |
| May 29, 2024 Filed May 30, 2024 18:10 UTC | Inhibrx Biosciences, Inc. INXB · Entity 4576 | GrantCommon Stock | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001493 · es240484863_4-lappe.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 125,000 F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. F3 · ownership.nature: These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust. Read SEC document |
| May 29, 2024 Filed May 30, 2024 18:10 UTC | Inhibrx Biosciences, Inc. INXB · Entity 4576 | GrantCommon Stock | 621,548 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-24-001493 · es240484863_4-lappe.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 621,548 F1 · price: The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. F2 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 16:41 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 60 | $25.02 | $1,501.25 |
DisclosureSEC source: 0001739614-23-000014 · wf-form4_167770687699240.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,486,192 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F2 · price: The shares were sold in multiple transactions at prices ranging from $25.005 to $25.07, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| January 24, 2023 Filed Jan 24, 2023 18:46 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 63 | $26.11 | $1,645.10 |
DisclosureSEC source: 0001739614-23-000010 · wf-form4_167460394406722.xml · nonDerivative · entry 3 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,486,252 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F5 · price: The shares were sold in multiple transactions at prices ranging from $26.105 to $26.13, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| January 24, 2023 Filed Jan 24, 2023 18:46 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 4,272 | $25.71 | $109,833.12 |
DisclosureSEC source: 0001739614-23-000010 · wf-form4_167460394406722.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,486,315 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F4 · price: The shares were sold in multiple transactions at prices ranging from $25.105 to $26.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| January 23, 2023 Filed Jan 24, 2023 18:46 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 21,665 | $25.36 | $549,363.74 |
DisclosureSEC source: 0001739614-23-000010 · wf-form4_167460394406722.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,490,587 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F2 · price: The shares were sold in multiple transactions at prices ranging from $25.00 to $25.61, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 18:11 UTC | Inhibrx, Inc. INBX · Entity 90351 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $23.30 | $0.00 |
DisclosureSEC source: 0001739614-23-000004 · wf-form4_167278749618241.xml · derivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments forthirty-six (36) months thereafter. Read SEC document |
| December 19, 2022 Filed Dec 20, 2022 16:59 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 754 | $26.29 | $19,819.57 |
DisclosureSEC source: 0001739614-22-000130 · wf-form4_167157357332535.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,512,252 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F4 · price: The shares were sold in multiple transactions at prices ranging from $26.00 to $26.86, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| December 19, 2022 Filed Dec 20, 2022 16:59 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 25,246 | $25.53 | $644,623.79 |
DisclosureSEC source: 0001739614-22-000130 · wf-form4_167157357332535.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,513,006 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F2 · price: The shares were sold in multiple transactions at prices ranging from $25.00 to $25.99, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 17:06 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 1,150 | $32.38 | $37,241.26 |
DisclosureSEC source: 0001739614-22-000124 · wf-form4_166880918186617.xml · nonDerivative · entry 7 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,538,252 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F9 · price: The shares were sold in multiple transactions at prices ranging from $31.97 to $32.75, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 17:06 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 912 | $30.67 | $27,969.22 |
DisclosureSEC source: 0001739614-22-000124 · wf-form4_166880918186617.xml · nonDerivative · entry 6 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,539,402 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F8 · price: The shares were sold in multiple transactions at prices ranging from $30.52 to $30.68, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 17:06 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 6,773 | $30.15 | $204,195.79 |
DisclosureSEC source: 0001739614-22-000124 · wf-form4_166880918186617.xml · nonDerivative · entry 5 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,540,314 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F7 · price: The shares were sold in multiple transactions at prices ranging from $29.47 to $30.31, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 17:06 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 1,767 | $28.86 | $50,991.03 |
DisclosureSEC source: 0001739614-22-000124 · wf-form4_166880918186617.xml · nonDerivative · entry 4 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,547,087 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F6 · price: The shares were sold in multiple transactions at prices ranging from $28.47 to $29.40, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 17:06 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 4,333 | $27.45 | $118,937.38 |
DisclosureSEC source: 0001739614-22-000124 · wf-form4_166880918186617.xml · nonDerivative · entry 3 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,548,854 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F5 · price: The shares were sold in multiple transactions at prices ranging from $27.04 to $28.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 17:06 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 4,106 | $26.57 | $109,097.65 |
DisclosureSEC source: 0001739614-22-000124 · wf-form4_166880918186617.xml · nonDerivative · entry 2 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,553,187 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F4 · price: The shares were sold in multiple transactions at prices ranging from $26.01 to $26.96, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 17:06 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 6,959 | $25.36 | $176,477.46 |
DisclosureSEC source: 0001739614-22-000124 · wf-form4_166880918186617.xml · nonDerivative · entry 1 Lappe Mark · CIK 0001366074 · Director · Chief Executive Officer Lappe Family Trust · CIK 0001821266 · To be Verified Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Lappe Family Trust Disclosed balance after: 2,557,293 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mark P. Lappe. F2 · price: The shares were sold in multiple transactions at prices ranging from $25.00 to $25.985, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.